Our group recently demonstrated the evidence of a significant synergism of metformin with gefitinib, a selective EGFR tyrosine kinase inhibitor (EGFR-TKI) on NSCLC cell lines [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.